
## Michael Brainin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1611426/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clobal, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
2	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
3	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
4	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
5	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	13.7	2,184
6	Clobal, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
7	Clobal, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
8	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 2018, 379, 2429-2437.	27.0	959
9	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
10	Clobal, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Clobal Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	13.7	740
11	World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International Journal of Stroke, 2022, 17, 18-29.	5.9	649
12	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
13	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
14	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
15	Post-stroke dementia $\hat{a} \in $ a comprehensive review. BMC Medicine, 2017, 15, 11.	5.5	442
16	Dysphagia Bedside Screening for Acute-Stroke Patients. Stroke, 2007, 38, 2948-2952.	2.0	428
17	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
18	The global burden of neurological disorders: translating evidence into policy. Lancet Neurology, The, 2020, 19, 255-265.	10.2	377

#	Article	IF	CITATIONS
19	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	13.7	335
20	COVID-19 and stroke—A global World Stroke Organization perspective. International Journal of Stroke, 2020, 15, 361-364.	5.9	314
21	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
22	World Stroke Organization (WSO): Global Stroke Fact Sheet 2019. International Journal of Stroke, 2019, 14, 806-817.	5.9	249
23	Toward an epidemiology of poststroke spasticity. Neurology, 2013, 80, S13-9.	1.1	245
24	Poststroke spasticity. Neurology, 2013, 80, S45-52.	1.1	216
25	Postâ€stroke cognitive decline: an update and perspectives for clinical research. European Journal of Neurology, 2015, 22, 229.	3.3	184
26	Primary stroke prevention worldwide: translating evidence into action. Lancet Public Health, The, 2022, 7, e74-e85.	10.0	156
27	Acute treatment and long-term management of stroke in developing countries. Lancet Neurology, The, 2007, 6, 553-561.	10.2	146
28	Stroke: Working Toward a Prioritized World Agenda. Stroke, 2010, 41, 1084-1099.	2.0	122
29	Cerebrolysin in Patients With Acute Ischemic Stroke in Asia. Stroke, 2012, 43, 630-636.	2.0	115
30	The Stroke Riskometerâ,,¢ App: Validation of a Data Collection Tool and Stroke Risk Predictor. International Journal of Stroke, 2015, 10, 231-244.	5.9	103
31	Priorities to reduce the burden of stroke in Latin American countries. Lancet Neurology, The, 2019, 18, 674-683.	10.2	102
32	Poststroke Chronic Disease Management: Towards Improved Identification and Interventions for Poststroke Spasticity-Related Complications. International Journal of Stroke, 2011, 6, 42-46.	5.9	94
33	Stroke: Working toward a Prioritized World Agenda. International Journal of Stroke, 2010, 5, 238-256.	5.9	89
34	Development of a Poststroke Checklist to Standardize Follow-up Care for Stroke Survivors. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, e173-e180.	1.6	84
35	Alteplase for Acute Ischemic Stroke. Stroke, 2015, 46, 746-756.	2.0	74
36	New Strategy to Reduce the Global Burden of Stroke. Stroke, 2015, 46, 1740-1747.	2.0	71

#	Article	IF	CITATIONS
37	Global prevention of stroke and dementia: the WSO Declaration. Lancet Neurology, The, 2020, 19, 487-488.	10.2	61
38	Organization of Stroke Care: Education, Referral, Emergency Management and Imaging, Stroke Units and Rehabilitation. Cerebrovascular Diseases, 2004, 17, 1-14.	1.7	58
39	Development of the Standards of Reporting of Neurological Disorders (STROND) checklist. Neurology, 2015, 85, 821-828.	1.1	57
40	Multidomain Lifestyle Interventions for the Prevention of Cognitive Decline After Ischemic Stroke. Stroke, 2015, 46, 2874-2880.	2.0	56
41	São Paulo call to action for the prevention and control of high blood pressure: 2020. Journal of Clinical Hypertension, 2019, 21, 1744-1752.	2.0	53
42	Evaluation of the Post Stroke Checklist: A Pilot Study in the United Kingdom and Singapore. International Journal of Stroke, 2014, 9, 76-84.	5.9	45
43	Patterns of Stroke Between University Hospitals and Nonuniversity Hospitals in Mainland China: Prospective Multicenter Hospital-Based Registry Study. World Neurosurgery, 2017, 98, 258-265.	1.3	45
44	Diabetes and the brain: issues and unmet needs. Neurological Sciences, 2014, 35, 995-1001.	1.9	44
45	Do Women With Atrial Fibrillation Experience More Severe Strokes?. Stroke, 2017, 48, 778-780.	2.0	44
46	Fixed-dose combination antihypertensive medications. Lancet, The, 2019, 394, 637-638.	13.7	44
47	Standards of practice in acute ischemic stroke intervention: international recommendations. Journal of NeuroInterventional Surgery, 2018, 10, 1121-1126.	3.3	40
48	Silent Brain Infarcts and Transient Ischemic Attacks. Stroke, 1995, 26, 1348-1352.	2.0	38
49	Post-stroke pneumonia at the stroke unit – a registry based analysis of contributing and protective factors. BMC Neurology, 2016, 16, 107.	1.8	37
50	Cerebrolysin: a multi-target drug for recovery after stroke. Expert Review of Neurotherapeutics, 2018, 18, 681-687.	2.8	36
51	Systematic dysphagia screening and dietary modifications to reduce stroke-associated pneumonia rates in a stroke-unit. PLoS ONE, 2018, 13, e0192142.	2.5	36
52	Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. European Journal of Epidemiology, 2015, 30, 569-576.	5.7	35
53	European Stroke Facilities Survey: The German and Austrian Perspective. Cerebrovascular Diseases, 2009, 27, 138-145.	1.7	34
54	What Is the Best Mix of Populationâ€Wide and Highâ€Risk Targeted Strategies of Primary Stroke and Cardiovascular Disease Prevention?. Journal of the American Heart Association, 2020, 9, e014494.	3.7	31

#	Article	IF	CITATIONS
55	Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. Circulation, 2021, 144, 1738-1746.	1.6	31
56	Myocardial Infarction as a Complication in Acute Stroke: Results from the Austrian Stroke Unit Registry. Cerebrovascular Diseases, 2014, 37, 147-152.	1.7	30
57	Cut stroke in half: Polypill for primary prevention in stroke. International Journal of Stroke, 2018, 13, 633-647.	5.9	29
58	Time Trends in Patient Characteristics Treated on Acute Stroke-Units. Stroke, 2013, 44, 1070-1074.	2.0	27
59	Acute Stroke Units in Austria Are Being Set Up on a National Level Following Evidence-Based Recommendations and Structural Quality Criteria. Cerebrovascular Diseases, 2003, 15, 29-32.	1.7	25
60	Stroke: Working toward a Prioritized World Agenda. Cerebrovascular Diseases, 2010, 30, 127-147.	1.7	25
61	Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. Neurology, 2016, 87, 861-869.	1.1	23
62	Antithrombotic Treatment of Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 1758-1765.	2.0	23
63	Advances in Stroke. Stroke, 2013, 44, 311-313.	2.0	22
64	ABCD3-I score and the risk of early or 3-month stroke recurrence in tissue- and time-based definitions of TIA and minor stroke. Journal of Neurology, 2018, 265, 530-534.	3.6	21
65	WSO and WHF joint position statement on population-wide prevention strategies. Lancet, The, 2020, 396, 533-534.	13.7	21
66	Conceptual framework for establishing the African Stroke Organization. International Journal of Stroke, 2021, 16, 93-99.	5.9	20
67	Standards of Practice in Acute Ischemic Stroke Intervention: International Recommendations. American Journal of Neuroradiology, 2018, 39, E112-E117.	2.4	19
68	Diabetes and thrombolysis for acute stroke: a clear benefit for diabetics. European Journal of Neurology, 2014, 21, 5-10.	3.3	17
69	Multidomain intervention for the prevention of cognitive decline after stroke – a pooled patientâ€ŀevel data analysis. European Journal of Neurology, 2018, 25, 1182-1188.	3.3	16
70	Explanation and Elaboration of the Standards of Reporting of Neurological Disorders Checklist: A Guideline for the Reporting of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology, 2015, 45, 113-137.	2.3	15
71	Stroke doctors: Who are we? A World Stroke Organization survey. International Journal of Stroke, 2017, 12, 858-868.	5.9	15
72	Neuroprotection in ischemic stroke: what does the future hold?. Expert Review of Neurotherapeutics, 2015, 15, 227-229.	2.8	14

#	Article	IF	CITATIONS
73	Prevention of Poststroke Cognitive Decline: ASPIS – a Multicenter, Randomized, Observer-Blind, Parallel Group Clinical Trial to Evaluate Multiple Lifestyle Interventions – Study Design and Baseline Characteristics. International Journal of Stroke, 2015, 10, 627-635.	5.9	14
74	Preventive effects of multiple domain interventions on lifestyle and risk factor changes in stroke survivors: Evidence from a two-year randomized trial. International Journal of Stroke, 2017, 12, 976-984.	5.9	14
75	Multi-level community interventions for primary stroke prevention: A conceptual approach by the World Stroke Organization. International Journal of Stroke, 2019, 14, 818-825.	5.9	14
76	IV thrombolysis in patients with ischemic stroke and alcohol abuse. Neurology, 2015, 85, 1592-1597.	1.1	13
77	Stroke Care in Central Eastern Europe: Current Problems and Call for Action. International Journal of Stroke, 2013, 8, 365-371.	5.9	12
78	Poststroke spasticity. Neurology, 2013, 80, S1-4.	1.1	12
79	Role and Impact of Cerebrolysin for Ischemic Stroke Care. Journal of Clinical Medicine, 2022, 11, 1273.	2.4	12
80	Psychosocial Distress, an Underinvestigated Risk Factor for Stroke. Stroke, 2013, 44, 305-306.	2.0	11
81	Tracking the global burden of stoke and dementia: World Stroke Day 2020. International Journal of Stroke, 2020, 15, 817-818.	5.9	10
82	Approaches to global stroke care during the COVID-19 pandemic. Stroke and Vascular Neurology, 2020, 5, 107-109.	3.3	10
83	Testing Devices for the Prevention and Treatment of Stroke and its Complications. International Journal of Stroke, 2014, 9, 683-695.	5.9	9
84	Reducing the burden of stroke: Opportunities and mechanisms. International Journal of Stroke, 2019, 14, 761-762.	5.9	9
85	Editorial: Stroke Units in Austria: structure, performance and results. Wiener Medizinische Wochenschrift, 2008, 158, 407-410.	1.1	8
86	Organizational Update. Stroke, 2017, 48, e341-e342.	2.0	8
87	Standards of practice in acute ischemic stroke intervention: International recommendations. Interventional Neuroradiology, 2019, 25, 31-37.	1.1	7
88	The African Stroke Organization — a new dawn for stroke in Africa. Nature Reviews Neurology, 2021, 17, 127-128.	10.1	7
89	Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke. Cardiovascular Diabetology, 2020, 19, 204.	6.8	5
90	COVID-19-related delays of botulinum toxin injections have a negative impact on the quality of life of patients with dystonia and spasticity: a single-center ambulatory care study. Journal of Neural Transmission, 2022, 129, 49-53.	2.8	5

#	Article	IF	CITATIONS
91	Polypill: Benefits Seen for Stroke and Other Outcomes. Stroke, 2022, 53, 2695-2701.	2.0	5
92	Determining the feasibility and preliminary efficacy of a stroke instructional and educational DVD in a multinational context: a randomized controlled pilot study. Clinical Rehabilitation, 2018, 32, 1086-1097.	2.2	4
93	The 1st International Conference on Advancement and Recommendations for Stroke Management (ICARSM) Held in Chengdu, China. International Journal of Stroke, 2007, 2, 231-231.	5.9	3
94	Use of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues. Expert Review of Neurotherapeutics, 2013, 13, 177-185.	2.8	3
95	European Stroke Organisation. Stroke, 2013, 44, .	2.0	3
96	Poststroke Neurocognitive Disorders Are Mostly Defined by Strategic Lesions. Stroke, 2018, 49, 2563-2564.	2.0	3
97	Standards of Practice in Acute Ischemic Stroke Intervention International Recommendations. Canadian Journal of Neurological Sciences, 2019, 46, 269-274.	0.5	3
98	Stroke epidemiology in China: which are the next steps?. Lancet Neurology, The, 2019, 18, 325-326.	10.2	3
99	Temporal trends in intracerebral hemorrhage: Evidence from the Austrian Stroke Unit Registry. PLoS ONE, 2019, 14, e0225378.	2.5	3
100	World Stroke Academy Revamped. International Journal of Stroke, 2013, 8, 59-59.	5.9	2
101	WSO Stroke Education Program in Vietnam 2008–2011: 8596 Hospital Doctors Attended in 58 Cities and Received a Certificate from the WSO and the Ministry of Health. International Journal of Stroke, 2013, 8, 148-149.	5.9	2
102	Second European Stroke Science Workshop. Stroke, 2014, 45, e113-22.	2.0	2
103	Stroke units around the world: the success story continues. Lancet, The, 2018, 391, 1970-1971.	13.7	2
104	Stroke emergency: Evidence favours laying the patient on the paretic side. Wiener Medizinische Wochenschrift, 2004, 154, 568-570.	1.1	1
105	World Stroke Day 2016 – "Face the facts: Stroke is treatable― International Journal of Stroke, 2016, 11, 844-845.	5.9	1
106	Overestimating the risk of aspiration in acute stroke. European Journal of Neurology, 2017, 24, e34.	3.3	1
107	C-REGS 2 - Design and methodology of a high-quality comparative effectiveness observational trial. Journal of Medicine and Life, 2021, 14, 700-709.	1.3	1
108	Essential stroke services. World Stroke Academy, 2013, 1, 15-15.	0.1	0

#	Article	IF	CITATIONS
109	Imaging for prediction of functional outcome and for assessment of recovery. , 0, , 64-81.		0
110	Report From the European Stroke Organization 2014. Stroke, 2014, 45, e188.	2.0	0
111	Cerebral Small-Vessel Disease. , 2019, , 202-212.		0
112	Poststroke Cognitive Recovery Prediction. Stroke, 2019, 50, 2647-2647.	2.0	0
113	International Impact of <i>Stroke</i> . Stroke, 2020, 51, 1036-1039.	2.0	0
114	Polypills for stroke prevention: they work and are effective. European Journal of Neurology, 2021, 28, 3879-3880.	3.3	0
115	Update on acute stroke therapy. Hamdan Medical Journal, 2015, 8, 315.	0.1	0
116	Experimental and Clinical Approaches to Recovery after Stroke. European Neurological Review, 2015, 10, 65.	0.5	0
117	Secondary stroke prevention offers now more choices and is critical to reduce the burden of recurrent stroke and death. Hamdan Medical Journal, 2018, 11, 1.	0.1	0
118	Prevention of stroke: Antihypertensives, cholesterol-lowering drugs, antithrombotics, anticoagulation, carotid surgery, and stenting. Hamdan Medical Journal, 2018, 11, 2.	0.1	0